| Drug Name |
Palbociclib |
| Drug ID |
BADD_D01654 |
| Description |
Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.[A176810]
Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth.[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.[L4894] |
| Indications and Usage |
Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. |
| Marketing Status |
Prescription |
| ATC Code |
L01EF01 |
| DrugBank ID |
DB09073
|
| KEGG ID |
D10372
|
| MeSH ID |
C500026
|
| PubChem ID |
5330286
|
| TTD Drug ID |
D00UZR
|
| NDC Product Code |
63539-189; 46708-910; 65129-1394; 52076-6263; 68554-0112; 61662-0014; 0069-0189; 76055-0036; 0069-0688; 63539-188; 63539-187; 0069-0284; 63539-688; 54893-0076; 0069-0486; 49386-022; 82245-0111; 63539-284; 76302-006; 0069-0188; 63539-486; 65015-885; 0069-0187; 71796-007 |
| Synonyms |
palbociclib | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one | Ibrance | PD 0332991 | PD0332991 | PD-0332991 |
